~~<i id='03E502E66C'><strike id='03E502E66C'><tt id='03E502E66C'><pre id='03E502E66C'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-10-03 01:07:57 Page View：1266

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sudafed saga points to U.S. issues with evaluating older drugs
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

focus

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Health Care Service Corp to buy Cigna Medicare Advantage plans

CignaisofficiallyexitingtheMedicarebusiness,agreeingtosellallofitsMedicareinsuranceplanstoHealthCare

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Zyn nicotine pouches become unlikely player in latest culture war

WikimediaCommonsSenateMajorityLeaderChuckSchumer(D-N.Y.)wantsthefederalgovernmenttoinvestigateZynnic